Glass Pharms news
All
- All
- Carbon Negative
- Education
- Medical Cannabis
- Milestones
- Pharmaceutical Innovation
- Protected Horticulture
- Uncategorized
Adam George joins Glass Pharms as Chairman
Adam George joins as Chairman Glass Pharms, the UK-based medical cannabis cultivation company, is delighted to announce the appointment of Adam George as Chairman. Adam officially joined the board on 1st December 2024.Glass Pharms chief executive, James Duckenfield said “We are delighted that Adam has joined the board. He brings unparalleled experience in pharmaceutical cannabis, with over 13 years spent at GW Pharmaceuticals including positions of CFO and UK managing director. He will support us in our mission to bring high quality pharmaceutical cannabis products to UK patients”Adam left GW Pharmaceuticals, now Jazz Pharmaceuticals, in 2020 and has other interests in businesses developing medicines derived from or inspired by plants, fungi and other natural sources.Adam George said, “It’s an exciting time to join Glass Pharms. With solid foundations laid through a world-class cultivation facility and an excellent team, the business is well-positioned to capitalise on the growing demand for high quality,...
CBPMs could save NHS £4B
Allowing CBPMs to be prescribed on the NHS for chronic pain could save the NHS almost £4B per annum, according to a study by York University, part-funded by Glass Pharms. We hope that NICE will review their study from 2019 which used assumptions of medicine cost which are not consistent with the current market.James Duckenfield, CEO of Glass Pharms, “Despite medicinal cannabis being legalised in 2018, there are still only a few NHS patients receiving unlicensed cannabis-derived medicines. We hope that NICE will review the evidence from this Health Economic Analysis and adapt its guidance accordingly. Now is the time to expand the NHS offering to allow unlicensed cannabis medicines to be prescribed for chronic pain.”
Releaf + Glass Pharms
Releaf + Glass Pharms agree landmark dealReleaf and Glass Pharms have agreed on a landmark multi-million pound deal that will see it grow 145kg of cannabis flower per month to supply CBPMs for Releaf's patients.Glass Pharms' continuous manufacturing facility will support the rapid growth of Releaf's clinic, believed to be the fastest growing in the UK.
R&D Collaboration with James Hutton Institute
Olivier Dehon (CFO, Glass Pharms), Prof. Derek Stewart (James Hutton Institute), Richard Lewis (MD, Glass Pharms), Dr Raul Huertas (James Hutton Institute)Glass Pharms and the Advanced Plant Growth Centre at The James Hutton Institute are to conduct a medical cannabis research program, funded by UKRI's Biotechnology and Biological Sciences Research Council (BBSRC). Pictured from left: Olivier Dehon (CFO, Glass Pharms), Prof. Derek Stewart (James Hutton Institute), Richard Lewis (MD, Glass Pharms), Dr Raul Huertas (James Hutton Institute).
Wiltshire Police Education Day
Wiltshire Police Education Day 19/08/2024 We were delighted to welcome the drug expert team from Wiltshire Police for an education day onsite at Glass Pharms. This was part of our ongoing process of mutual education and collaboration with law enforcement.
Glass Pharms Launches Own-Branded Products to UK Market
Glass Pharms has announced the launch of a new range of own-branded CBPMs UK-based medical cannabis cultivator Glass Pharms has announced the launch of a new range of own-branded ‘cannabis-based products for medicinal use’ (CBPMs).
Devon & Cornwall Police Education Day
Devon & Cornwall Police Education Day 27/06/2024We were delighted to welcome the Drug Expert and Drugs Focus Desk teams from Devon & Cornwall Police for an education day onsite. Thanks to them for their time. Our view is that working closely with law enforcement is the best way to foster mutual understanding and create the right environment for legitimate Medical Cannabis.
Drone Helps Climate Control
Drone footage - click on image We aim to have the same climate in our greenhouse throughout the year. That means that in the summer we actually get too much light which turns into heat - yes, even in the UK! Heat stress can lead to hermaphrodism in cannabis. This in turn leads to fertilisation of flowers which generate seeds. Seeds are not permitted in medical cannabis in the UK. We use an AI controlled drone to apply a diffusion coating to our glass roof. The diffused light doesn't cast shadows that would create uneven light for the plants. Diffusion allows our climate computer to use shading algorithms as part of our climate control strategy and a small part of the reason we guarantee no seeds in our product. cannabis seeds agricultural drone
In Conversation with Rt Hon. Wes Streeting MP
In conversation with Wes Streeting Our CEO, James Duckenfield, attended an event at The Royal Society of Medicine where Rt. Hon. Wes Streeting MP spoke with passion about the NHS and his personal battle with kidney cancer. Of note was his desire to work with the Life Sciences industry and make the UK a destination for life sciences and manufacturing. He would like to see public services treat those who it serves as customers and allow patients to self-refer to specialists.
First Domestic Medical Cannabis Well Received
UK Patients Have Been Waiting 6 Entire Years for This to Happen!!
Business of Cannabis
Business of Cannabis Coverage Milestone for UK Medical Cannabis as Glass Pharms’ First Domestically Grown Medical Cannabis Arrives
First UK Grown Cannabis Flower CBPM
Coverage in the Times Sunday Times exclusively covers the news that Glass Pharms brings the first Cannabis flower CBPM to market, ending the reliance on imported flower since the law was changed in 2018.
- « Previous
- 1
- 2
- 3
- 4
- Next »